Sutro Biopharma
STRO
64 hedge funds and large institutions have $64.8M invested in Sutro Biopharma in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 32 closing their positions.
338% more call options, than puts
Call options by funds: $35K | Put options by funds: $8K
24% more capital inflows, than outflows
Capital inflows: $16.3M | Capital outflows: $13.2M
2.74% more ownership
Funds ownership: 62.98% → 65.72% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less funds holding
Funds holding: 87 → 64 (-23)
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
63% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Affinity Asset Advisors
New York
|
+$6.39M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.18M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.81M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$700K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Suvretta Capital Management
New York
|
-$5.63M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.68M |
| 3 |
Tang Capital Management
San Diego,
California
|
-$1.36M |
| 4 |
BlackRock
New York
|
-$487K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$387K |
STRO Hedge Fund Activity: Q4 2025 in Review
64 of the 8,296 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2025, worth a combined $64.8M — up 40% from $46.4M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of STRO and 12 opened new positions — a net loss of 20 holders — while 26 trimmed existing stakes and 15 added.
The largest buyer was Affinity Asset Advisors, adding an estimated $6.39M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $5.63M sold.
- 64 institutional investors held Sutro Biopharma (STRO) as of Q4 2025, down from 87 in Q3 2025.
- Funds reported $64.8M of Sutro Biopharma stock for Q4 2025, up 40% quarter-over-quarter.
- 12 funds opened new Sutro Biopharma positions in Q4 2025 and 32 closed out, a net change of -20 holders.
- The largest Sutro Biopharma buyer in Q4 2025 was Affinity Asset Advisors, an estimated $6.39M added.
- The largest Sutro Biopharma seller in Q4 2025 was Suvretta Capital Management, an estimated $5.63M sold.
Based on aggregated 13F filings for Q4 2025.